Ensysce Biosciences Inc. (ENSC)
| Bid | 2.36 |
| Market Cap | 5.86M |
| Revenue (ttm) | 7.41M |
| Net Income (ttm) | -6.58M |
| EPS (ttm) | -3.51 |
| PE Ratio (ttm) | -0.7 |
| Forward PE | -46.4 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 2.48 |
| Volume | 67,452 |
| Avg. Volume (20D) | 355,782 |
| Open | 2.47 |
| Previous Close | 2.47 |
| Day's Range | 2.39 - 2.48 |
| 52-Week Range | 1.62 - 14.67 |
| Beta | 1.11 |
| Ex-Dividend Date | n/a |
About ENSC
undefined
Analysts project revenue of ... Unlock content with Pro Subscription
5 days ago · accessnewswire.com
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clini...
1 month ago · accessnewswire.com
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~ SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Comp...
1 month ago · accessnewswire.com
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~ ~ Ensysce Biopharma Leader to Deliver O...
2 months ago · accessnewswire.com
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program UpdatesInitiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Prot...
